/
Other
Adult Subject
26
Pipeline Programs↗
21
Active Trials↗
137
Companies Involved↗
Adult Subject is an emerging landscape with 26 programs across 137 companies. The most active players are Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., SineuGene Therapeutics Co., Ltd., Corcept Therapeutics.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 125
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
92%
Small molecule
23 of 25 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 25 classified programs, each share of the total. Modality classified for 100% of 26 pipeline programs.
Analysis
Trial Status
419
clinical trials
Completed356 · 85%
Unknown status19 · 5%
Terminated14 · 3%
Not yet recruiting9 · 2%
Withdrawn9 · 2%
Recruiting8 · 2%
Other4 · 1%
Clinical Trials
Trial Activity
419 trials
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Recruiting·TTheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)·Phase 1·NCT06917079·387 enrolled
Evaluation of 627 in Healthy Adult Subjects
Not yet recruiting·SSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.·Phase 1·NCT07065136·108 enrolled
Page 1 of 28
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)